Breakthrough multi-cancer early detection tests have the potential to expand testing options for rare cancers by testing for dozens of cancers from a single drop of blood. Providing a pathway to Medicare coverage once these tests are FDA-approved and clinical benefit is shown will expand access to cancer innovation and make time for bucket lists. Literally.